18-Jun-2026
TipRanks (Thu, 18-Jun 7:35 AM ET)
After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
Globe Newswire (Wed, 27-May 9:00 AM ET)
PRNewswire (Wed, 20-May 7:00 AM ET)
InMode to Present at Upcoming Investor Conferences and Events
PRNewswire (Wed, 13-May 8:30 AM ET)
PRNewswire (Wed, 6-May 5:23 PM ET)
PRNewswire (Mon, 13-Apr 7:00 AM ET)
InMode to Present at the 25th Annual Needham Virtual Healthcare Conference
PRNewswire (Tue, 24-Mar 8:30 AM ET)
InMode Launches Ambitious Share Repurchase Program Targeting 10% of Outstanding Shares
Market Chameleon (Fri, 13-Mar 3:28 AM ET)
Market Chameleon (Tue, 10-Feb 4:18 AM ET)
Market Chameleon (Mon, 2-Feb 4:33 AM ET)
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
Inmode Ltd. - trades on the NASDAQ stock market under the symbol INMD.
As of June 18, 2026, INMD stock price climbed to $13.40 with 492,952 million shares trading.
INMD has a beta of 0.99, meaning it tends to be less sensitive to market movements. INMD has a correlation of 0.18 to the broad based SPY ETF.
INMD has a market cap of $816.31 million. This is considered a Small Cap stock.
Last quarter Inmode Ltd. - reported $82 million in Revenue and $.25 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.08.
In the last 3 years, INMD traded as high as $48.25 and as low as $12.72.
The top ETF exchange traded funds that INMD belongs to (by Net Assets): IEFA, SCZ, IXUS, IZRL, AVDV.
INMD has underperformed the market in the last year with a price return of +0.4% while the SPY ETF gained +26.9%. INMD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -0.4% and -1.6%, respectively, while the SPY returned +13.5% and -1.1%, respectively.
INMD support price is $13.21 and resistance is $13.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INMD shares will trade within this expected range on the day.
